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Introduction 
Obstructive airways disease is a group of condition 
distinguished by increased resistance and obstruction in the 
air passages, especially during expiration. The term  OAD  
includes bronchial asthma; chronic obstructive pulmonary 
disease, consisting of chronic bronchitis and emphysema;  
bronchiectasis; cystic fibrosis and bronchiolitis [1]. 
COPD is a disease state characterized by airflow limitation 
that is not fully reversible. The airflow obstruction is usually 
both progressive and associated with an abnormal 
inflammatory response of the lungs to noxious particles and 
gas.  There are around 50 million patients with COPD in 
India and COPD is the second leading cause of death in 
India. An estimate suggests that COPD will rise from the 
sixth to the third most common cause of death worldwide by 
2020 [2]. 
Diagnosis of OAD is based on the patient`s history, signs, 
and symptoms, and on the results of spirometry and other 
pulmonary function tests. Spirometry assesses the obstruction 
of expiratory airflow, which is the characteristic functional 
defect in OAD. Spirometry is the most effective way of 
determining the severity of obstructive airway diseases [3]. 
C-reactive protein was first isolated in 1930 from the plasma 
of patients with pneumococcal pneumonia, CRP was so 
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named because it binds to the C-polysaccharide of the 
pneumococcus. Modern molecular studies have determined 
that CRP is a member of the pentraxin family of proteins. It 
comprises five protomers, each of 206 amino acids, 
molecular weight 23 kDa, arranged in cyclic symmetry. With 
the participation of Ca2 ions, it binds various proteins and 
phospholipids, particularly phosphocholine. It opsonizes 
particles and also activates complement via the classical 
pathway, but its actual biological function is unknown [4]. 
In the lungs, CRP has a protective function by acting against 
bacteria and apoptotic cells. Activated epithelial cells, 
alveolar macrophages and other inflammatory cells in COPD 
release IL-6 into the circulation. CRP is primarily produced 
by hepatocytes in response to IL-6 stimulation [5]. This 
stimulates an acute-phase response and increases the level of 
plasma CRP. C-reactive protein appears in blood in the acute 
stages of various inflammatory disorders but is undetectable 
in the blood of healthy persons [6]. 
Worldwide studies show that it has variable roles in COPD, 
some showing correlation with spirometric lung function 
while others show no significant relation. We would, 
therefore, like to explore its role in our study population and 
also try to explore whether it could become an independent 
predictor of disease outcome in COPD. 
Materials and Methods 
Study design: A cross-sectional study was conducted among 
50 COPD patients attending Respiratory Medicine outpatient 
services in Regional Institute of Medical Sciences (RIMS), 
Imphal from January 2015 to September 2016. Patients aged 
18-67 were included in the study after obtaining Ethical 
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Latex Slide test kit was used to estimate serum c-reactive protein. Results: The present study was conducted on fifty COPD 
patients in which serum CRP level showed positive correlation with COPD (p=0.002) but serum CRP level with spirometric 
parameters showed significant negative correlation; FEV1 (r=-0.451, p=0.001), FEV1/FVC (r=-0.617, p<0.001) and PEFR (r=-
0.398, p=0.004). Conclusion: In our study we found an association between serum CRP level and severity of COPD and Plasma 
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approval from the Research Ethics Board, RIMS, Imphal. 
The participants were recruited by Purposive sampling. 
Diagnosed COPD patients sent from Respiratory Medicine 
OPD, RIMS, Imphal were included in this study. 
The patients with chronic disorders like hypertension, 
diabetes mellitus, cardiovascular diseases, bleeding disorders, 
inflammatory disorders, infection, malignancy and patients 
who had recent surgery were excluded from the study. 
Computerized Spirometer Helios 401 of the Recorders and 
Medicare System, Chandigarh, India was the instrument used 
to measure lung volumes and capacities. The Helios software 
contains a set of prediction equations for computation of 
predicted parameter values. 
The procedure was explained to the patient followed by a 
demonstration. The patient was asked to “take as deep a 
breath as possible” and then “blast as fast and hard as you 
can” and “keep blowing until I ask you to stop” preferably at 
least 3 seconds followed by a rapid inhalation (inspiration). A 
tight seal was ensured around the mouthpiece. During the 
test, a soft nose clip was used to prevent air from escaping 
through the nose. Coaching was active and vigorous; 
instructions were repeated as necessary. Three consecutive 
maneuvers were performed with a rest of 5 to 10 minutes 
between two maneuvers.  
The best result among the three tests was recorded in the 
proforma. The results were compared with the predicted 
values for the same age, sex, height, and weight. Patients 
were classified on the basis of the GOLD Classification of 
COPD (2006) [7]. 
The study variables which include Forced Vital Capacity 
(FVC), Forced Expiratory Volume in one second (FEV1), 
FEV1/FVC ratio, Forced Expiratory Flow during 25-75% of 
expiratory flow (FEF 25-75%), and Peak Expiratory Flow Rate 
(PEFR),  were recorded by Helios Computerized Spirometer 
Model No. 401, in a sitting position. Spirometric values are 
better when done in a standing position but sitting posture is 
usually preferred because of the risk of fall due to cough 
syncope when done in standing. 
BeneSpheraTM CRP Latex Slide test kit of  Avantor 
Performance Materials India Ltd, Dehradun, Uttarakhand, 
was used to estimate serum c-reactive protein in human. The 
test was expected to be positive with serum CRP levels 
between 0.6 and 100mg/dl.  
Statistical analysis 
The collected data were entered and analyzed using 
IBM SPSS Statistics V21.0 (IBM Corporation, US). 
Summarizations of data for frequency distribution for 
variables of interest were carried out by using descriptive 
statistics such as mean, standard deviation and percentages. 
Chi-square test was employed to test the association between 
asthma with variables of interest. A p-value of <0.05 was 
considered to be statistically significant. 
Results 
A total of 50 patients with the chronic obstructive pulmonary 
disease were included in the study. Of which Maximum 
percentage (92%) of patients belong to the age group (38-67 
years ) while minimum percentage (8%) of the patients 
belong to age group (18-37 years). About two-thirds of the 
Obstructive Airway Disease patients were male. Out of 50, 
32% patients were non-smoker, 38% were smoker, and 30% 
were ex-smokers and smoking pack years was less than 100 
in 38 % and more than 100 in 62 % in the study population. 
Socio-demographic characteristics like age, sex, smoking 
history were recorded. Thorough physical examination, 
degree of airflow obstruction and serum C-reactive protein 
were recorded after obtaining Prior written informed consent 
form from all the participants. Patients were classified on the 
basis of the GOLD Classification of COPD. 
We found that 22% of COPD patients were in moderate 
category (FEV1/FVC < 0.70 and FEV1=0.50-0.80), 18% of  
patients were in severe category (FEV1/FVC < 0.70, and 
FEV1=0.30-0.50), and 14% of patients were classified as very 
severe (FEV1/FVC < 0.70, and FEV1 < 0.30). Only 6% of the 
patients had mild airflow limitation while 40% of COPD 
patients had no airflow limitation during spirometry.  
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Spirometric  
parameters 
Minimum Value 
(%pred) 
Maximum Value 
(%pred) 
Mean 
(%pred) 
Standard Deviation 
FVC 36.00 158.00 83.96 30.98 
FEV1 9.00 155.00 61.16 32.63 
FEV1/FVC 11.00 111.00 71.06 20.25 
FEF25-75% 6.00 138.00 34.20 27.53 
PEFR 6.00 87.00 34.70 19.70 
Severity of 
COPD 
CRP 
Total p-value* LESS THAN  
6 mg/L 
6 mg/L 12 mg/L 
Normal 
Mild 
Moderate 
Severe 
Very severe 
Total 
19 
1 
5 
4 
1 
30 
1 
2 
3 
3 
2 
11 
0 
0 
3 
2 
4 
9 
20 
3 
11 
9 
7 
50 
0.002 
Table 1. Mean±SD of FVC, FEV1, FEV1/FVC, FEF25-75%, and PEFR in COPD patients (n=50) 
Table 2. Association of the serum CRP level with the severity of COPD 
*Chi-Square Test 
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Table 1 shows the lung function test values of COPD patients 
as measured by a spirometer. FVC values were within normal 
limit. But the mean values of FEV1, FEF25-75%, and PEFR 
were lower. The results suggest that in the COPD patients 
larger and smaller airways both were involved. 
Above table shows the association between serum CRP level 
and severity of COPD. Total 9(18%)  COPD patients had 
serum CRP level 12mg/L, in which  3(6%) patients belong to 
moderate category, 2(4%) patients belong to severe category, 
and 4(8%) patients belong to very severe category. And 11
(22%) COPD patients had serum CRP level 6mg/L, it 
included; 1(2%) patient with normal spirometry, 2(4%) 
patients were in mild category, 3(6%) patients were in each 
moderate and severe category, and 2(4%) patients were in 
very severe category (p=0.002). 
Table 3. Correlation of different parameters of 
spirometry and age with serum CRP level in COPD 
patients (n=50) 
 
*Pearson`s bivariate correlation coefficient 
Table 3 shows that age, FEV1, FEV1/FVC, and PEFR were 
negatively correlated with serum C-reactive protein. 
Discussion 
COPD is the second leading cause of death in India and the 
disability from this disease is substantial and is expected to 
rise in India and worldwide. There are evidences pointing 
towards smoking being a risk factor COPD and for increased 
clinical symptoms and poorer lung function in COPD 
patients. Hence all possible efforts should be taken to make 
people quit smoking, by adopting more awareness and 
control programs. But smoking cessation is challenging so 
education advice, behavioral intervention along with drug 
therapy like nicotine replacement therapy with gums, patch 
or inhaler can be tried for better results.  
The treatments available today have a minimum impact on 
the disease progression, so early diagnosis and treatment are 
necessary. Measures such as screening with spirometric tests 
in high-risk individuals especially the smokers in age group 
of 40-55 should be considered to reduce the mortality and 
morbidity due to COPD. In this study we were trying to find 
whether CRP levels can be used as a valid tool and an 
independent predictor of disease outcome in COPD so that it 
could be used to evaluate the clinical, prognostic and 
therapeutic outcomes. 
The present study was conducted on fifty COPD patients in 
which serum CRP level showed positive correlation with 
COPD (p=0.002) but serum CRP level with spirometric 
parameters showed significant negative correlation;FEV1 (r=-
0.451, p=0.001), FEV1/FVC (r=-0.617, p=0.000) and PEFR 
(r=-0.398, p=0.004). 
Variables 
Correlation coeffi-
cient (r)* 
p-value 
FEV1 -0.451 0.001 
FEV1/FVC -0.617 <0.001 
PEFR -0.398 0.004 
There are evidences supporting our study from previous 
research work conducted by Moreton RE and Kennedy CR 
reported that CRP concentration in patients (age range 0.03-
16.1 years, median: 6.7 years) with cystic fibrosis ranged 
from 0.01-304 mg/L while in healthy children ranged from 
0.01-2.8 mg/L and correlation between CRP and FVC% 
predicted was significant (r=-0.781; p<001) [8]. 
Gan and colleagues aggregated data from five cross-sectional 
studies and estimated an average mean increase in serum 
CRP of 1.85 mg/L in individuals with stable COPD [9]. 
There were similar results in the study conducted by Fares M 
et al [10]. They showed that CRP level >1.1mg/L in infants 
with bronchiolitis. Hsieh MH et al [11] found a good 
correlation between serum hs-CRP and HRCT scores in the 
patients with stable non-cystic fibrosis bronchiectasis. 
 Similar results were shown in the study conducted by Tores 
et al [12] and Seemungal et al [13] the mean CRP level 
between the control group and COPD group were compared 
and was different by greater than 3.3 mg/L, which was found 
to be significant (P<0.001).  
Conclusion 
In this study, we were trying to find whether CRP proteins 
levels can be used as a valid tool in COPD patients so that it 
could be used to evaluate the clinical, prognostic and 
therapeutic outcomes. In our study we found association 
between serum CRP level and severity of COPD and Plasma 
CRP may be used as a marker of prognosis in COPD as small 
increase is associated with poorer prognosis in COPD.  
Limitations 
The serum CRP has been used for evaluation of COPD and 
other inflammatory conditions but several factors might 
affect serum levels of CRP. CRP may be elevated in obese 
individuals and also in people who have the habit of 
smoking. Ageing is also another confounding factor. Further 
longitudinal studies are necessary to evaluate whether CRP 
could be used as an independent predictor of disease 
outcome. 
Ethical clearance: Ethical approval was obtained from the 
Research Ethics Board, RIMS, Imphal before the beginning 
of the study.  
Source of funding: Self  
Conflict of Interest: Nil 
Acknowledgment 
We acknowledge great help received from the scholars whose 
articles are cited and included in the references of this 
manuscript. 
References 
[1] Weinberger SE, Rosen IM. Disturbances of respiratory 
function. In: Loscalzo J, editor. Harrison`s Pulmonary 
and Critical Care Medicine. New Delhi: McGraw-Hill; 
2010. [Google Scholar] 
[2] Mannino DM, Buist AS. Global burden of COPD: risk 
factors, prevalence, and future trends. Lancet 2007;370
(9589):765-73. [Google Scholar] 
[3] Bellamy D. Spirometry in practice: A practical guide to 
using spirometry in primary care. 2nd ed. London: BTS 
Karthika et al.   Evaluating serum C-reactive protein level in patients with COPD. 
Int. J. Curr. Res. Physiol. Pharmacol. 2019;3(4):1-4. 
 4 
 
COPD Consortium; 2005. [Google Scholar] 
[4] Block JL. Evaluation of cardiac injury and function. In: 
McPherson RA, Pincus MR, editors. Henry`s Clinical 
Diagnosis and Management by Laboratory Methods. 
21st ed. New Delhi: Elsevier; 2009. [Google Scholar] 
[5] Yoshida M, Sakuma J, Hayashi S, Abe K, Saito I, 
Harada S, et al. A histologically distinctive interstitial 
pneumonia induced by overexpression of the interleukin 
6, transforming growth factor β1, or platelet-derived 
growth factor B gene. Proc Natl Acad Sci USA 
1995;92:9570. [Google Scholar] 
[6] Sonnenwirth AC. Serological tests in infectious disease-
II. In: Sonnenwirth, Jarett L, editors. Gradwohl`s 
Clinical Laboratory Methods and Diagonosis. 8th ed. 
New Delhi: B.I. Publications Ltd; 1990. [Google 
Scholar] 
[7] Global strategy for the diagnosis, management, and 
prevention of chronic obstructive pulmonary disease 
(2006). Available at: http://www.goldcopd.org. 
Accessed September 19, 2016. 
[8] Moreton RE, Kennedy CR. C reactive protein 
concentrations in cystic fibrosis. Arch Dis Child 
1988;63:958-60. [Google Scholar] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[9] Gan WQ, Man SFP, Senthilselvan A, Sin DD. 
Association between chronic obstructive pulmonary 
disease and systemic inflammation: a systematic review 
and a meta-analysis. Thorax 2004;59:574. [Google 
Scholar] 
[10] Fares M, Mourad S, Rajab M, Rifai N. The use of C-
reactive protein in predicting bacterial co-infection in 
children with bronchiolitis. N Am J MedSci 2011;3
(3):152-6. [Google Scholar] 
[11] Hsieh MH, Fang YF, Chen GY, Chung FT, Liu YC, 
Wu CH, et al. The role of the high-sensitivity C-reactive 
protein in patients with stable non-cystic fibrosis 
bronchiectasis. Pulm Med 2013;2013(1):1-8. [Google 
Scholar] 
[12] Torres J. P. de, Cordoba-Lanus E., López-Aguilar C., 
Fuentes M. Muros de, Garcini A. Montejo de, Aguirre-
Jaime A. C-reactive protein levels and clinically 
important predictive outcomes in stable COPD patients. 
The European Respiratory Journal 2006;27:902-
7. [Google Scholar] 
[13] Seemungal T. A., Lun J. C., Davis G., Neblett C., 
Chinyepi N., Dookhan C.. Plasma homocysteine is 
elevated in COPD patients and is related to COPD 
severity. International Journal of Chronic Obstructive 
Pulmonary Disease 2007;2:313-21. [Google Scholar] 
Karthika et al.   Evaluating serum C-reactive protein level in patients with COPD. 
Int. J. Curr. Res. Physiol. Pharmacol. 2019;3(4):1-4. 
